Literature DB >> 17877441

Off-label use of antipsychotics: are we mad?

Camilla Haw1, Jean Stubbs.   

Abstract

The off-label prescribing of antipsychotic drugs to psychiatric patients of all ages is very common. Such off-label use is a necessary part of the art of psychiatry but brings with it increased responsibilities for the prescriber as, if the patient suffered an adverse reaction, liability would rest with the prescriber and/or their employers. This article reviews the frequency and nature of the off-label prescribing of antipsychotic drugs for psychiatric indications to children, adults and the elderly. It also reviews the evidence base for doing so in a variety of common, and also some less common, clinical situations. The review is mainly concerned with off-label indications but a short section on high dose antipsychotics is also included. The review concludes that the off-label prescription of antipsychotics frequently lacks the support of robust clinical trials. When prescribing off-label, the prescriber must carry out a careful risk assessment of the risks and benefits for the individual patient. They should also inform the patient that the prescription is off-label.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17877441     DOI: 10.1517/14740338.6.5.533

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  15 in total

1.  Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.

Authors:  James I Wasserman; Rebecca J Barry; Lisa Bradford; Nicholas J Delva; Richard J Beninger
Journal:  Psychopharmacology (Berl)       Date:  2012-01-12       Impact factor: 4.530

2.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

3.  Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016.

Authors:  Mikkel Højlund; Anton Pottegård; Erik Johnsen; Rune A Kroken; Johan Reutfors; Povl Munk-Jørgensen; Christoph U Correll
Journal:  Br J Clin Pharmacol       Date:  2019-05-11       Impact factor: 4.335

4.  Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.

Authors:  Gudrun Hefner; Jan Wolff; Sermin Toto; Pamela Reißner; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2022-09-07       Impact factor: 3.850

5.  Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study.

Authors:  Johan Lökk
Journal:  Neuropsychiatr Dis Treat       Date:  2010-04-07       Impact factor: 2.570

6.  Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients.

Authors:  Steffen Moritz; Maarten J V Peters; Anne Karow; Azra Deljkovic; Peter Tonn; Dieter Naber
Journal:  Ment Illn       Date:  2009-12-17

7.  Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System.

Authors:  Michael De Santis; Jiamei Lian; Xu-Feng Huang; Chao Deng
Journal:  Int J Mol Sci       Date:  2016-11-22       Impact factor: 5.923

8.  Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.

Authors:  Stephane Cheung; Yukinobu Hamuro; Jörg Mahlich; Takanobu Nakahara; Rosarin Sruamsiri; Sunny Tsukazawa
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

Review 9.  Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?

Authors:  Sean Kim; Gayoung Lee; Eric Kim; Hyejin Jung; Jongwha Chang
Journal:  J Res Pharm Pract       Date:  2017 Jan-Mar

10.  Off-label prescription of psychiatric drugs by non-psychiatrist physicians in three general hospitals in Germany.

Authors:  Caroline Lücke; Jürgen M Gschossmann; Teja W Grömer; Sebastian Moeller; Charlotte E Schneider; Aikaterini Zikidi; Alexandra Philipsen; Helge H O Müller
Journal:  Ann Gen Psychiatry       Date:  2018-02-08       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.